Summary
Prostate cancer can be treated by Cyberknife, and the numbers of patients treated and the number of units sold by Accuray (ARAY:NASDAQ) will very likely increase dramatically over the next 5-10 years.
Analysis
Prostate cancer cases are very common in US men. Cyberknife has been proposed as a treatment option for radiation of the prostate. Cyberknife has been used successfully in the treatment of other forms of cancer throughout the US. While clinical papers are still lagging behind clinical use, it is reasonable to assume that Cyberknife radiation will be at least as effective as other forms of radiation, with similar, if not better, side effect profiles. It will be five years before clinical trials with randomization will be published, but I suspect that most radiation oncology centers will proceed with offering the treatment without waiting for these publications.
